This infection affects, or threatens, millions of poorer people around the world, but there are no vaccines and only limited drug treatment options. Despite various efforts, the number of new chemical entities identified and entering development as anti-leishmanials has been very low. Researchers from CGID, in partnership with others, have investigated plant-derived options derived from common ivy and found some very promising options for future development.